Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Researchers at UBC have identified a rare inherited mutation in the CDK12 gene linked to aggressive, metastatic prostate cancer — and it could already be detectable with existing genetic tests. Every man found carrying the mutation had developed metastatic disease by age 62. Adding CDK12 to standard hereditary cancer panels could help at-risk families catch the disease earlier, when treatment is still curative.
Researchers at the University of British Columbia have identified a previously unknown inherited form of aggressive prostate cancer tied to mutations in the CDK12 gene. Until now, CDK12 changes were thought to arise spontaneously within tumors — not be passed down through families. But after analyzing genetic data from more than 4,500 people with aggressive prostate cancer, the team found five unrelated men who all carried inherited CDK12 mutations and all developed metastatic disease between ages 44 and 62.
The tumors of these men displayed a distinctive molecular "fingerprint" confirming that the inherited mutation was directly driving cancer development. The study, published in Cancer Discovery, also found hints that the mutation may be linked to ovarian cancer risk, with several carriers having relatives who had ovarian cancer — and one ovarian cancer patient found to carry the same inherited CDK12 mutation with a matching tumor signature.
By the Numbers:
Why it matters: No new technology is needed to act on this discovery. CDK12 can be added to existing hereditary cancer gene panels, meaning this finding could move from lab to clinic relatively quickly — giving at-risk families a real shot at early detection and curative treatment.